MAP2K7 and melanoma: Targeted treatments of BRAF gene-mutated melanoma with BRAF (vemurafenib, dabrafenib) and MEK inhibitors have prolonged progression-free and overall survival.1–3 Interestingly, side effects differ among these targeted therapies.